Abdominal Aortic & Junctional Tourniquet (AAJT)

Product No. #05246
NSN: 6515-01-616-4999
Abdominal Aortic & Junctional Tourniquet (AAJT)
Made In USA Badge

The Abdominal Aortic & Junctional Tourniquet is the first device to provide stable and complete occlusion of flow of blood to the lower extremities, pelvis and upper extremities.

Read More

Retail $550.00
$524.98
You Save $25.03 (5%)
Add to Wishlist
This product cannot be shipped outside the United States (except APO/FPO addresses).
Purchase of this medical device requires that the user have supervision from a licensed medical practitioner. Devices requiring such supervision may be labeled "Caution" or "RX only". Ensuring this supervision is the purchaser's responsibility. By adding this item to the cart I verify that I accept these terms.

Description

Description

 

The Abdominal Aortic & Junctional Tourniquet (AAJT) is the first device to provide stable and complete occlusion of flow of blood to the lower extremities, pelvis and upper extremities. It has 510(k) clearance from the FDA for difficult to control inguinal and pelvic hemorrhage. It can be applied to the mid-abdomen, tightened and inflated and may remain on for up to an hour safely. It is also FDA cleared for all junctional hemorrhage sites (axilla and inguinal placements) and can remain on for up to 4 hours in these locations. The AAJT is the ONLY junctional tourniquet to have saved human life in upper and lower junctional hemorrhage. It is also the ONLY junctional hemorrhage to have human research showing it is safe and effective.

The FDA clearance provides for the following changes:

  • The AAJT is now the only device to carry an indication for pelvic bleeding, a common complication in junctional injuries as noted by the Committee on Tactical Combat Casualty Care.
  • The AAJT is cleared for use in the groin and axilla for 4 hours.
  • The hard time limit for the abdominal placement has been removed; it should be left in place until directed by a physician to be removed.
  • There is no longer any contraindication for penetrating abdominal injuries.
  • The AAJT has the capability to stabilize the pelvis.

The AAJT is simple enough to be applied by non-medical providers, since its application doesn’t require knowledge of the vascular anatomy. The AAJT has demonstrated the ability to stay in place and maintain efficacy during patient movement in confined space rescue, drags, and hasty extraction.

The AAJT provides a rapid application of pneumatic compression to the aorta at the abdominal-pelvic junction to occlude blood flow in the common iliac and inguinal arteries as well as the subclavian artery at the axilla placement site. The target of the compression for pelvic-junctional hemorrhage is the aortic bifurcation, which has historically been identified in relation to the umbilicus or the superior margin of the iliac crests. Compression at the level of the aortic bifurcation in the abdomen is effective, safe, and cleared by the FDA. The target of compression for upper junctional bleeding is the axilla with the compression stopping blood flow in the proximal subclavian artery near the sternoclavicular junction and this site placement is also cleared by the FDA. The device can be applied in either location in approximately 30-45 seconds.

This circumferential device utilizes a belt, windlass and pneumatic pressure to compress the aorta. The belt and windlass together greatly increase the stability of the compression. The pneumatic wedge-shaped bladder provides focused pressure to squeeze the blood vessels passing through the lower abdomen and preventing flow. In essence the AAJT acts as a valve to figuratively ‘turn the faucet off’ and prevent the further flow of blood out of wounds below its application site.

In a recent study when the AAJT was applied to the groin, it was effective using less pressure than that required for the Combat Ready Clamp (CRoC) or Junctional Emergency Treatment Tool (JETT) to work. The large bladder of the AAJT applies pressure over a large surface area allowing for lower overall tissue pressure. This lower operating pressure allows for a reduced risk of tissue and nerve injury.

Benefits & Features:

  • The AAJ is the only device to stop bleeding in interpelvic injuries safely which is a common complication in lower junctional trauma.
  • It is the only device to save human life in upper and lower junctional bleeding
  • It is the only device proven to be capable of stopping hemorrhage even if a casualty loses the entire shoulder complex
  • It is the only device with human research that supports its safety and efficacy
  • It is the only device with independent international validation of its effectiveness
  • Speed of application (mean time of application 45 sec)
  • It provides definitive cessation of arterial blood flow below the umbilicus or subclavian flow at or near the sternoclavicular junction
  • Operates at lower tissue pressures for increased comfort and decreased risk of secondary tissue and nerve injury
  • The AAJT is the most stable junctional device during patient movement due to not using a mechanical fulcrum that pulls away from the body during application
  • The AAJT provides the capability to be used as a triage and assessment tool. First application allows a blood free field to identify wounds and apply appropriate intervention.
  • No effect on diaphragm movement during application
  • It can be applied to one inguinal region for one sided inguinal or leg injuries with pressures far lower than the CRoC or JETT
  • It has a larger volume and more physiologically focused bladder design than any other pneumatic device
  • It is one device for all junctional bleeding

Available on ECAT.

NSN: 6515-01-616-4999

 

Specifications

Specifications

Weight: 1 lb
Dimensions: 9" x 8" x 2"
Pressurization: Manual, by inflator bulb
Deflation: Built-in 300 mm Hg relief valve and thumb screw valve
Click here for more specifications

Reviews

Reviews

There are no reviews yet. Be first to Write a Review (requires login).

Mi9 Retail